Relmacabtagene Autoleucel in Patients With LBCL
To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world
Large B-cell Lymphoma
BIOLOGICAL: Relmacabtagene Autoleucel
ORR, Percentage of participants with CR or PR, 6 months
CRR, Complete response rate, 6 months|DOR, Duration of response, 6 months|Progression-Free Survival (PFS), PFS is defined as the time from the Relmacabtagene Autoleucel infusion date to the date of disease progression per Lugano classification or death from any cause., 6 months|Overall Survival (OS), OS is defined as the time from Relmacabtagene Autoleucel infusion to the date of death from any cause., 6 months|Adverse events (AEs), Types, frequency, and severity of adverse events and laboratory anomalies Physiological parameter, 6 months
This is a post-marketing, multicenter, observational real-world study, including prospective and retrospective studies. The purpose of this study is to collect efficacy and safety data over a 6-month period following treatment of adult patients with r/r LBCL with Relmacabtagene autoleucel. The treating physicians in the study will determine the most appropriate diagnostic and therapeutic regimen for their patients based on clinical practice.There will be no therapeutic intervention as a result of this study. There will be no subgroups of any kind in this study, and subgroup analyses will be performed based on the actual data collected during the analysis.